BNT 116
Alternative Names: BNT-116Latest Information Update: 31 Aug 2026
At a glance
- Originator BioNTech
- Class Antineoplastics; Cancer vaccines; Immunotherapies; RNA vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Non-small cell lung cancer
Most Recent Events
- 20 Apr 2026 Updated efficacy data from the phase I LuCa-MERIT-1 trial in Non-small cell lung cancer presented at the 117th Annual Meeting of the American Association for Cancer Research (AACR-2026)
- 06 Sep 2025 Efficacy, and adverse event data from the phase I LuCa-MERIT-1 trial in non-small cell lung cancer presented at the 26th World Conference on Lung Cancer (WCLC-2025)
- 09 Jul 2025 Phase-I development is ongoing in Hungary, USA, Germany, Poland, Spain, Turkey and United Kingdom (NCT05142189)